key: cord-298079-hgdyxk98
authors: Hsu, Jeffrey J.; Al‐Saffar, Farah; Ardehali, Reza; Baas, Arnold S.; Carlson, Margrit; Cruz, Daniel; Deng, Mario; Fan, Ashley; Fraschilla, Stephanie; Gaynor, Pryce; Kamath, Megan; Kubak, Bernard M.; Schaenman, Joanna; Stimpson, Emily; Vucicevic, Darko; Ardehali, Abbas; Nsair, Ali
title: Heart Transplantation in the Early Phase of the COVID‐19 Pandemic: A Single‐Center Case Series
date: 2020-07-12
journal: Clin Transplant
DOI: 10.1111/ctr.14042
sha: 
doc_id: 298079
cord_uid: hgdyxk98

The infectious disease Coronavirus Disease 2019 (COVID‐19) was declared a pandemic by the World Health Organization in March 2020. The impact of COVID‐19 on solid organ transplantations, including heart transplantation, is currently unclear. Many transplant programs have been forced to swiftly re‐evaluate and adapt their practices, leading to a marked decrease in transplants performed. This trend has been due to various factors, including increased donor COVID‐19 screening scrutiny and recipient waiting list management in anticipation of COVID‐19 critical care surge capacity planning. In the face of these unknown variables, determining when and how to proceed with transplantation in our population of patients with end‐stage cardiomyopathies is challenging. Here, we describe our center’s experience with orthotopic heart transplantation (OHT) in one of the country’s pandemic epicenters, where we performed eight OHTs in the first two months after community spread began in late February 2020.

On February 26, 2020, the first case of community spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the United States (US) was confirmed. 1 deaths. 2 The ongoing pandemic has presented a challenging predicament for organ transplantation programs. The combination of a protracted asymptomatic incubation period of SARS-CoV-2 and the lack of capacity for rapid testing of potential donors to avoid transmission of SARS-CoV-2 were challenges to transplant programs. 3 Further, the effects of SARS-CoV-2 in highly immunosuppressed patients in the early post-transplant period are currently unclear. Nonetheless, it has been assumed that any significant viral infection in this patient cohort would be detrimental, which has been demonstrated in early reports. 4 In addition, cardiovascular disease has emerged as a risk factor for mortality with COVID-19. 5 Indeed, the number of patients inactivated on the heart transplant waitlist more than doubled between the weeks of March 8 and March 15 in the US, and the number of weekly orthotopic heart transplantation (OHT) procedures decreased from 76 to 50 during the same timespan according to the United Network for Organ Sharing. 6 These trends persisted through the week of April 5, when only 43 OHTs were performed, but by mid-May, returned to pre-pandemic levels.

The potential risks of OHT in this setting need to be weighed against the wellestablished risk of mortality on the waitlist in patients with advanced heart failure (HF). In this context, we describe our center's OHT experience in this early phase of the pandemic.

Located in one of the country's epicenters (Los Angeles, California), our program performed eight OHTs in the first two months since community spread began. As detailed below, there have been no COVID-19-related complications thus far.

This article is protected by copyright. All rights reserved

From early March 2020 to late April 2020, our program performed eight OHTs, and the details of each case are summarized in Table. Patient ages ranged from 48 to 65 years old, with three male and two female patients transplanted during this period. One patient was transplanted after Status 2 listing, given the need for percutaneous temporary left ventricular assist device (LVAD) support. Five patients were transplanted after Status 3 listing, and two patients were transplanted after outpatient Status 4 listing. One patient (Case 7) underwent dual organ (heart-kidney) transplantation.

Per our program protocol, all eight patients were maintained on a triple immunosuppression regimen post-transplant -tacrolimus (target trough 10-15 ng/mL), mycophenolate mofetil (1 gram orally twice daily), and high-dose corticosteroids. Three of the eight patients received induction immunosuppression with basiliximab. The decisions of whether or not to use basiliximab in each case was based on our program's routine protocol, and they were not influenced by concern of the developing pandemic. 

This article is protected by copyright. All rights reserved Three of the eight patients were readmitted to the hospital during this period: two for worsening volume overload and one for severe hyperglycemia. There have been no COVID-19 related complications in any of the eight patients thus far.

The COVID-19 pandemic poses complex challenges for organ transplant programs around the world, particularly in epicenters, 7 forcing many programs to re-evaluate their practices. These decisions must weigh the known benefit of OHT against the potential risk of concerns. 6 While located in a COVID-19 epicenter in the US, our hospital is a quaternary care center that prepared itself to accommodate a surge in patients with COVID-19. As cases of COVID-19 rose in our hospital, our surge planning protocol triggered the formation of designated intensive care units (ICUs) for the care of critically ill patients with COVID-19.

These COVID-19 designated ICUs were physically separate from the ICUs where our patients are roomed pre-and post-transplantation. Fortunately, during the period described, we did not near reaching our hospital's ICU bed capacity. Further, our hospital is a specialized extracorporeal membrane oxygenation (ECMO) center, and during the period described in this report, we managed two patients with COVID-19 who required venovenous ECMO.

In this setting, our program made the decision to continue heart transplantation, and our OHT volume remained unchanged during this time. Interestingly, the number of donor organ offers our program received during the period described did not differ significantly

This article is protected by copyright. All rights reserved from the number of offers seen in the prior two years. Critical to our efforts were the following adaptations:

 Frequent reassessment of our hospital and ICU bed capacity, These policies are similar to those described by other centers in high endemicity areas. 8 Central to our plan was the requirement that, once testing became available, both the donor and recipient undergo RT-PCR testing for SARS-CoV-2. UCLA developed an internal RT-PCR test with a high negative predictive value, and for donors in our local organ procurement organization, we had samples couriered to our labs for rapid testing (<24 hour turnaround time early in the pandemic course, improving to <4 hours later) when testing was not immediately available at the donor hospital. This protocol increased our confidence that infection was unlikely in potential donors, reducing risk to our recipients and our surgical procurement team. Indeed, our program would decline offers if the donor hospital could not provide a BAL sample for testing. Current recommendations from the International Society of Heart and Lung Transplantation (ISHLT) is for all potential donors to undergo PCR-based testing for SARS-CoV-2. 10 While ISHLT recommendations do not state a preferred

This article is protected by copyright. All rights reserved specimen, they note that the tracheal aspirate and BAL samples yields higher sensitivity, 9 which factored in to our decision to require BAL samples for donors.

Starting in early April 2020, with increased testing capacity available, our hospital implemented policies whereby all patients admitted to the hospital required PCR-based testing of an NP sample for SARS-CoV-2. Also, all patients undergoing procedures (including right heart catheterizations and transplant surgeries) were required to have PCRbased testing of an NP sample within 48 hours prior to the procedure. While our program did not require COVID-19 testing in order to list a transplant candidate, these measures taken together strengthened our confidence in the safety of proceeding with heart transplantation in our recipients.

Additionally, strict enforcement of our hospital's visitor policy, which restricted visitors from entering patients' rooms, as well as a reinforced education program on social distancing and hand hygiene were critical elements for patients who underwent transplantation. Furthermore, Los Angeles County issued "Stay at Home" orders on March 20, 2020, which may have helped to protect patients from exposure and infection after their discharge.

In our eight cases performed during the period of pandemic onset (Table) , none have become infected with SARS-CoV-2 to date, despite the growing number of cases in Los Angeles (Figure 1) . Importantly, the first two cases did not receive either donor or recipient testing for SARS-CoV-2, as they occurred during the initial period in which testing was unavailable or greatly limited. Additionally, two of the eight cases underwent transplant after waiting at home (Status 4). The impact of social distancing and hand hygiene education that post-transplant patients receive likely played a strong role. Supporting this notion is the observation that a low rate of SARS-CoV-2 infection was seen in OHT recipients in Wuhan. 11 Importantly, we actively decided to continue performing surveillance endomyocardial biopsies per our normal protocol. However, we have required that all of our outpatients have COVID-19 testing within 48 hours before their procedure to reduce the exposure risk to team members.

This article is protected by copyright. All rights reserved

We and others have reported cases of COVID-19 in longer-term OHT recipients, which had relatively benign clinical courses. 12, 13 However, a recent study found a 25% case fatality rate among OHT patients, 14 and a full understanding of COVID-19 in this population remains to be determined. Similarly, the impact of SARS-CoV-2 infection in a patient with a newly transplanted cardiac graft is unclear, as to our knowledge, there are have yet to be any cases reported at the time of this communication. While only 3 of our 8 patients above received induction immunosuppression therapy, we continued to make decisions on induction following our standard protocol, not solely for the purpose of infection prevention.

More evidence is needed to determine the risks of SARS-CoV-2 infection in newly transplanted patients.

In summary, we describe our center's experience with 8 patients with varied paths to transplantation (Statuses 2-4) who underwent successful OHT with no COVID-19-related complications to date, with no changes in our protocols for induction, immunosuppression, and post-transplant surveillance monitoring. Their post-transplant lengths of stay were not different from our program's averages. Additional evidence is needed to more fully determine the risk profile of performing OHTs in this COVID-19 pandemic. Nonetheless, these outcomes are likely to be affected by the magnitude of COVID-19 spread in each community, and the impact of the relaxation of local "Stay at Home" orders is to be determined. Although Los Angeles was one of the earliest urban centers in the country to experience high levels of infection, early social distancing interventions slowed the infection rate; therefore, our experience may not be generalizable to other areas undergoing higher peaks of infection activity. Continuous reassessment of the local community situation relative to the pandemic, with reciprocally frequent re-evaluation of each transplant program's policies, are needed in this dynamic societal and medical landscape (Figure 2) .

CDC Confirms Possible Instance of Community Spread of COVID-19 in

World Health Organization. Coronavirus disease (COVID-19) pandemic

Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility

Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

United Network for Organ Sharing (UNOS) Accessed

COVID-19: A Global Transplant Perspective on Successfully Navigating a Pandemic

Accepted Article This article is protected by copyright. All rights reserved

Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Guidance from the International Society of Heart and Lung Transplantation Regarding the SARS CoV-2 Pandemic

Epidemiological and Clinical Characteristics of Heart Transplant Recipients During the 2019 Coronavirus Outbreakin in Wuhan, China: A Descriptive Survey Report. The Journal of Heart and Lung Transplantation

COVID-19 in a High-Risk Dual Heart and Kidney Transplant Recipient

First Cases of COVID-19 in Heart Transplantation From China. The Journal of Heart and Lung Transplantation

Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease

The Los Angeles Times' Independent Tally of Coronavirus Cases in California

We would like to thank all members of the UCLA Heart Transplantation Program for their tremendous contributions to our program and tireless efforts in continuing to deliver the highest quality of care to our patients and their families during this incomparably challenging time.

This article is protected by copyright. All rights reserved Sources of Funding: None.

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved Accepted Article